PPARG and type 2 diabetes mellitus: The use of PPARγ antagonists is also a novel therapeutic strategy being explored, for example, as it pertains to the ability of PPARγ antagonists to regulate lipid metabolism in mouse models of type 2 diabetes (T2DM), like the Gleevec, a renowned anticancer drug, acts as a PPARγ ligand without classical agonism, inhibiting PPARγ phosphorylation at S273 (Rieusset et al., 2002; Burton et al., 2008; Wang et al., 2015; Choi et al., 2016), cervical cancer (An et al., 2014), and to inhibit adipose tissue differentiation (Wright et al., 2000).